Although the anti TNF-a agent known as etanercept has shown promising results in several small-scale studies with patients with HF [153,154], large-scale studies have failed to reproduce these results and have yielded neutral [155] or even negative results [156] with regard to mortality and hospitalization incidence, thus dampening the enthusiasm for the treatment of chronic inflammation in CHF. This evidence concerns the gene TNF and hydrops fetalis.